A potential role for daptomycin in enterococcal infections: What is the evidence?

Rafael Cantón*, Patricia Ruiz-Garbajosa, Ricardo L. Chaves, Alan P. Johnson

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    75 Citations (Scopus)

    Abstract

    Nosocomial infections caused by enterococci present a challenge for clinicians because treatment options are often limited due to the widespread occurrence of strains resistant to multiple antibiotics, including vancomycin. Daptomycin is a first-in-class cyclic lipopeptide that has proven efficacy for the treatment of Gram-positive infections. Although methicillin-resistant Staphylococcus aureus has been the most prominent target in the clinical development of daptomycin, this agent has demonstrated potent bactericidal activity in enterococcal infection models and has been used for the treatment of enterococcal infections in humans. In recent years, large-scale susceptibility studies have shown that daptomycin is active against >98% of enterococci tested, irrespective of their susceptibility to other antibacterial agents. This lack of cross-resistance reflects the fact that daptomycin has a mode of action distinct from those of other antibiotics, including glycopeptides. While there are limited data available from randomized controlled trials, extensive clinical experience with daptomycin in enterococcal infections (including bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections and urinary tract infections) has been reported. This growing body of evidence provides useful insights regarding the efficacy of daptomycin against enterococci in clinical settings.

    Original languageEnglish
    Article numberdkq087
    Pages (from-to)1126-1136
    Number of pages11
    JournalJournal of Antimicrobial Chemotherapy
    Volume65
    Issue number6
    DOIs
    Publication statusPublished - 2 Apr 2010

    Bibliographical note

    Funding Information:
    This work, including writing support, was funded by Novartis Pharma AG.

    Keywords

    • Cyclic lipopeptide antibiotics
    • Gram-positive bacteria
    • Nosocomial infections
    • Vancomycin resistance

    Fingerprint

    Dive into the research topics of 'A potential role for daptomycin in enterococcal infections: What is the evidence?'. Together they form a unique fingerprint.

    Cite this